Introduction: useful safety panel screening uses useful assays, kinase/transporter profiling, and advanced visualization to detect off-concentrate on liabilities early, increasing preclinical security assessments. Just previous 7 days, a late-stage drug candidate unexpectedly showed adverse results that hadn’t appeared in before assays, elevatin